Loading patent…
AssigneesImmunocore Limited, The United States of America, as represented by the Secretary, Dept. of Health and Human Services
InventorsPaul F. Robbins, Richard A. Morgan, Steven A. Rosenberg, Alan David Bennett
Estimating the term…
The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.
-39. (canceled)
A method of treating or preventing a disease in a host, comprising administering to the host a pharmaceutical composition comprising a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells, in an amount effective to treat or prevent the disease in the host.
A method of identifying a candidate adoptive immunotherapy T cell receptor (TCR), consisting of:
Dependencies are inferred from the claim text.